Shrugging off a phase 3 disappointment, Travere Therapeutics has won the first FDA approval for a treatment for rare kidney ...

On today’s episode of the pharmaphorum podcast, host Jonah Comstock speaks with Thomas Goetz, former executive editor of ...

Rare neurological disease has undergone a meaningful shift over the past decade. Advances in human genetics, expanded access ...

For now, the FDA is simply asking trial sponsors to make sure they meet the required reporting standards, but it has also ...

Novo Nordisk has become the latest big pharma group to forge an alliance with AI giant OpenAI, seeking to turbocharge its ...

But you cannot fail early if you cannot see risk clearly. Drug development still relies heavily on sequential experimentation ...

Hemab Therapeutics, chaired by former Alnylam chief executive John Maraganore, has published its redacted IPO prospectus with ...

Revolution Medicines thinks it could transform the treatment of pancreatic cancer – one of the hardest forms to treat – based ...

Novo Nordisk has agreed to buy Akero Therapeutics and its drug candidate for metabolic dysfunction-associated steatohepatitis (MASH) for $4.7 billion upfront, shortly after claiming FDA approval to ...

In our penultimate video from this year’s LSX World Congress, web editor Nicole Raleigh spoke with Mike Cooke, CEO of AmacaThera, a leading developer of next-generation hydrogel-based drug delivery ...

AI algorithms that can identify which patients are most likely to benefit from a drug recently backed for NHS use as a colorectal cancer (CRC) therapy have been developed by scien ...

The phase 1 BEHOLD-1 trial of B7-H4-directed mocertatug rezetecan (Mo-Rez, formerly HS-20093) showed an objective response rate (ORR) of 62% in platinum-resistant ovarian cancer (PROC) and 67% in ...